EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Belzutifan for Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 64
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2022 AND VI 36 AND IP 1
Results: 9
1
2
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 59
- By:
- Publication type:
- Article
3
Looking Ahead: What's Next for Hematology/Oncology in 2022?
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 7
- By:
- Publication type:
- Article
4
Strategies to Avoid Malpractice Suits.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 66
- Publication type:
- Article
5
Remembering Michael J. Hennessy Sr.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 67
- Publication type:
- Article
6
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 21, doi. 10.46883/2022.25920939
- By:
- Publication type:
- Article
7
Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 51
- By:
- Publication type:
- Article
8
Tripathy Details Importance of Both Clinical Research and Patient Advocacy.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 13
- Publication type:
- Article
9
Reviewed in ONCOLOGY ®: Gender Representation on Guideline Panels.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 1, p. 6
- By:
- Publication type:
- Article